Edwards shareholders approve 7M share increase in Long-Term Stock Program

Edwards Lifesciences Corp

Stockholders authorized 7M additional shares, raising total available to 341.5M under the amended program.
All 9 director nominees reelected; proposal received between 428M and 474M For votes each.
Advisory vote on named executive officer compensation passed with ~89% of votes cast.
Ratification of PwC as independent auditor for FY2026 approved with ~89% of votes cast.
Stock program amendment (Proposal 4) passed with 456.7M For (96% of votes cast, excluding broker non-votes).

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Edwards Lifesciences Corp shareholders approved Advisory proposal regarding the Company’s named executive officer compensation at the 2026-05-07 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2026-05-07

Exact text from the filing

Proposal 2 : The advisory proposal regarding the Company’s named executive officer compensation was approved as set forth below: For Against Abstain Broker Non-Votes 424,961,639 50,924,101 0 27,211,476

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Edwards Lifesciences Corp shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-05-07 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-05-07

Exact text from the filing

Proposal 3 : Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was approved as set forth below: For Against Abstain Broker Non-Votes 446,283,142 56,814,075 0 27,211,476

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Edwards Lifesciences Corp shareholders approved Election of nine directors at the 2026-05-07 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-05-07

Exact text from the filing

Proposal 1 : All the nominees for director listed in Proposal 1 were elected to serve until the Company’s next annual meeting of stockholders and until their respective successors are duly elected and qualified as set forth below: Nominee For Against Abstain Broker Non-Votes Leslie C. Davis 461,819,765 13,184,241 881,733 27,211,476 David T. Feinberg, MD 473,746,144 1,812,520 327,076 27,211,476 Kieran T. Gallahue 457,045,403 18,518,195 322,142 27,211,476 Leslie S. Heisz 454,955,195 20,567,869 362,676 27,211,476 Paul A. LaViolette 428,701,646 45,445,276 1,738,817 27,211,476 Steven R. Loranger 446,216,434 28,909,945 759,361 27,211,476 Ramona Sequeira 474,260,552 1,295,682 329,506 27,211,476 Nicholas J. Valeriani 441,224,095 34,327,820 333,825 27,211,476 Bernard J. Zovighian 459,179,727 16,257,009 449,004 27,211,476

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Edwards Lifesciences Corp shareholders approved Approval of the Company’s Amended and Restated Long-Term Stock Incentive Compensation Program at the 2026-05-07 meeting.

Proposal: equity plan
Outcome: passed
Meeting: 2026-05-07

Exact text from the filing

Proposal 4 : The approval of the Company’s Amended and Restated Long-Term Stock Incentive Compensation Program was approved as set forth below: For Against Abstain Broker Non-Votes 456,675,201 19,210,539 0 27,211,476

View on SEC.gov

Browse all shareholder votes →

Edwards Lifesciences Corp filing history →

Source: SEC EDGAR

accession 0001099800-26-000028

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.